BI 1744

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyPulmonary Disease, Chronic Obstructive

Phase 1

Relative Bioavailability of of Olodaterol and Ketoconazole

CompletedNCT01153711

Boehringer IngelheimHealthy, Pulmonary Disease, Chronic Obstructive

Start: 2010-05-31Updated: 2014-04-30

Relative Bioavailability of Olodaterol and Fluconazole

CompletedNCT01153724

Boehringer IngelheimHealthy, Pulmonary Disease, Chronic Obstructive

Start: 2010-05-31Updated: 2014-06-10

Phase 3

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

CompletedNCT00931385

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2009-06-30Updated: 2014-07-01

Related Papers

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.

2014-08-0934 citations